Clinical Phenotyping and Resource Biobank Core

The primary goal of the C-PROBE is to develop an infrastructure that will serve as an interface between patients in the clinical care settings and biomedical investigators conducting translational research in kidney disease.

Markus Bitzer
Markus Bitzer


The C-PROBE objectives are as follows:  

  1. To establish a collaborative agreement for operating a biomedical research core among five institutions:
    • St. Clair Nephrology Research
    • The University of Michigan Nephrology Program
    • The Wayne State University School of Medicine Nephrology Program
    • Temple University, Philadelphia
    • Levine Children's Hospital
  2. To establish an ethnically diverse pool of human research subjects consisting of individuals with kidney disease.
  3. To develop a streamlined infrastructure for recruitment of human subjects into clinical and translational research protocols using a customized, secure, web-based relational clinical research data management system.
  4. To maintain a centralized bank of biological specimens and clinical data. 

Information/Samples collected on each subject include: 

Phenotypic Data: 

Biological Specimens:

  • Urine Supernatant – 14.4 mL (Maximum distributed for any research study is 2.5 mL)
  • Urine Pellet (re-suspended in RNAlater) – 0.2 mL
  • Blood Plasma – 14.4 mL (Maximum distributed for any research study is 1.0 mL)
  • Blood Serum – 9.6 mL (Maximum distributed for any research study is 1.0 mL)
  • RNA Paxgene tube (1)
  • DNA – DNA Paxgene tube (1) or DNA processed with Gentra system 


Description of Currently Enrolled C-PROBE Subjects